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ABSTRACT
Caffeine is a stimulant thought to activate the pleasure centre in the brain, commonly used in the general public
for purposeful attempt to alter mood, and also commonly perceived to be a bladder irritant with associated
urgency and frequency symptoms. Mental health diagnosis, such as depression, is also associated with
overactive bladder. Taken together, it is plausible that women with overactive bladder symptoms along with
comorbid mental health symptoms may also show higher caffeine intake but no data exist. This pilot study’s
purpose was to determine in women with overactive bladder, if those with a mental health diagnosis (we
included anxiety, depression, post-traumatic stress disorder and bipolar diagnosis) consume a significantly
higher amount of caffeine than those without any of these diagnoses. Secondary analysis was performed on
data from women with overactive bladder recruited into a longitudinal parent study on beverage management.
All parent study participants met criteria of urgency and voiding more than seven times per day. Each kept
a detailed 3-day diary of beverage intake. From the total parent study pool of 61, we identified 14 women
with a comorbid mental health diagnosis as described above and 47 without when interviewed at baseline.
Women with mental health diagnosis demonstrated higher median baseline caffeine intake per day than their
counterparts without mental health diagnosis: 240·2 mg (range: 72·3–576·0 mg) versus 174·3 mg (range:
0–567·6 mg), which was marginally significant (p = ·053). Volume of caffeinated beverage intake did not differ
significantly. In women with overactive bladder and comorbid mental health symptoms, higher caffeine intake
may be a previously unrecognized link. Cause and effect is unknown between the three conditions of overactive
bladder, mental health disorders and higher caffeine intake; but this initial data support the need for further
research.
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BACKGROUND
It is a common practice among health care providers to
relate overactive bladder (OAB) symptoms to excess
consumption of caffeine. A typical first-line treatment
for women presenting to their health care providers
with OAB is to decrease or eliminate caffeinated
beverages. Although data linking caffeine to OAB
symptoms are sparse, there is an abundance of expert
advice to decrease or eliminate caffeine, for instance
as published on well-respected websites: ‘National
Association for Continence’ (NAFC, 2008); ‘Cleveland
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Clinic’ (2008); ‘National Institute for Clinical Excellence’
(NICE, 2006).
Data show that higher rates of bladder disorders
(voiding frequency, urgency and incontinence) are
linked with mental health conditions (Zorn et al., 1999;
Weissman et al., 2000; Nygaard et al., 2003; Melville
et al., 2005; Moghaddas et al., 2005; Fitzgerald et al.,
2007; Link et al., 2007), though the underlying mech-
anism involved is not understood. Causal factors sug-
gested include some alteration stemming from sexual
abuse (Link et al., 2007), a candidate gene (Weissman
et al., 2000), and noradrenaline and serotonin dysreg-
ulation (DeGroat, 2002). None of these explanations
completely explain the linkage between bladder disor-
ders and mental health conditions.
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A tenable companion hypothesis is that OAB and
mental health diagnoses are linked in part by caffeine,
one of the world’s most popular mood-altering drugs.
Caffeine is known to activate the pleasure centre in
the brain (Kelly and Mac Evilly, 2001; Lorist and
Tops, 2003). Thus, it is reasonable to assume that
caffeine, a readily available and socially accepted
drug, could be used as a form of self-medication
for those experiencing mood disorders. If so, and if
caffeine is also a bladder irritant, then women with a
mental health diagnosis may inadvertently trigger or
exacerbate symptoms of OAB, symptoms which might
otherwise not exist at clinically significant levels.
RESEARCH QUESTION
To begin to explore this possible connection, we
performed a small pilot study using data available from
a longitudinal parent study on beverage management
as treatment for OAB. Using only the baseline data
from the parent study, we tested the hypothesis
that women with comorbid OAB and mental health
diagnoses would demonstrate higher caffeine intake
on 3-day diaries than those with OAB alone.
SAMPLE
The parent study (analysis of longitudinal data is
ongoing) recruited 61 community-dwelling women
through newspaper advertising after obtaining Institu-
tional Review Board (IRB) approval. Inclusion criteria
included: female, age 18 and older, greater than seven
voids per day or two per night, daily consumption of
at least 16 ounces of beverages potentially irritating
to the bladder (coffee, tea, alcohol or caffeinated bev-
erages), greater than 32 ounces of overall beverage
intake per day, and an answer of ‘yes’ to the question,
‘Do you experience frequent, strong feelings of urgency
to empty your bladder?’ Exclusion criteria included
women who were pregnant, had diabetes, were tak-
ing diuretic pills, and women who experienced pain
when urinating or had frequent urinary tract infections.
In addition, women who had surgery for incontinence
within the past year could not participate because of
the likelihood of the surgical procedure causing the
symptoms of OAB. Cognitively impaired adults were
excluded because of the difficulty in diary keeping and
consistency in educational delivery. Informed consent
was obtained and participants enrolled.
The study design for this secondary analysis
of baseline data was retroactive case control. We
retrospectively assigned women as ‘cases’ if baseline
data from the parent longitudinal study included a
diagnosis of one of the following mental health
diagnoses: anxiety, depression, post-traumatic stress
disorder or bipolar disorder (23%, n = 14), or if
medications indicated the same. Those women from
the parent study without a mental health diagnosis
served as controls (77%, n = 47).
DATA COLLECTION METHODS
Upon entry into the longitudinal parent study, women
were given a DVD as well as written instructions on
how to keep a detailed 3-day diary at home and were
instructed to be as specific as possible. They were
given precise examples on how to record beverage
intake on their diary (e.g. Starbucks caffeinated coffee,
grande 16 ounces). Food intake was not recorded, so
only data on caffeine consumed through beverages
were available for analysis. The diary form used
was designed for the parent study and is appended
(Appendix A). The parent intervention study requires
data on both intake and bladder and bowel output,
as well as symptom change measured by OAB
questionnaires (Bower et al., 2001; Coyne et al., 2002;
de Wachter, 2003). Although women from the parent
study completed three 3-day diaries, only the intake
data from the baseline diary were utilized for analysis
in this report.
A nurse practitioner gathered additional information
in a clinical setting through an interview and ques-
tionnaires, including information about each subject’s
past and current medical diagnoses, medications, and
demographics; height and weight were measured.
Participants were assigned identification numbers to
preserve anonymity.
DATA ANALYSIS
The secondary analysis represented here was con-
ducted as pilot information to determine worthiness of
future investigation on the potential linkage between
caffeine, mental health conditions and OAB.
Data management of the baseline 3-day intake
portion of the participants’ diaries for this analysis
was conducted as follows. Caffeine was quantified
in milligrams using a variety of sources to obtain
precise content calculations. Primarily, we relied on
USDA data and specific brand websites (Coca-Cola,
Pepsi, Folgers, etc.). Details of caffeine conversions by
product are appended (Appendix B). Three-day tallies
of caffeine intake in milligrams, caffeinated beverage
intake in ounces and total beverage intake in ounces
were all reduced to daily averages. Descriptive analysis
was used to characterize the sample and graphical
portrayal of the data provided additional information.
Scatter-plots were used to examine data on age or
body mass index (BMI) in relation to caffeine intake.
For hypothesis testing, distribution free statistics
were used when data were not normally distributed.
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The non-parametric Mann–Whitney U test was used
to test for differences in caffeine intake, measured in
milligrams, between women with and without a mental
health diagnosis and an independent t-test was used
to determine whether volume of caffeinated beverage
intake, measured in ounces, differed between groups.
A p-value of ·05 was used to determine significance. A
priori power analysis was not conducted as we relied
on the fixed sample size of the parent study that was
primarily designed for longitudinal analysis.
RESULTS
The women were on average 48 years old, ranging
from 20 to 88 years, and 87% were Caucasian, 59%
had at least one vaginal delivery and 65% had a
college education. All women met OAB criteria of
voiding greater than seven times per day and/or greater
than two times per night and said ‘yes’ on entrance
screening to the question ‘Do you experience frequent,
strong feelings of urgency to empty your bladder?’
The daily average of milligrams of caffeine intake
was 205·1 mg (standard deviation = 140·8). Amount
of caffeine intake in relation to age and BMI are
portrayed graphically in Figures 1 and 2.
To display the data according to cases and
controls, Figure 3 shows box plots of caffeine intake
Figure 1 The scatter-plot shows that caffeine intake and age do not appear
to correlate in this sample.
Figure 2 The scatter-plot shows that caffeine intake and body mass index
(BMI) do not appear to correlate in this sample.
in milligrams. The median (range) of caffeine intake
for cases was 240·2 (72·3–576·0) mg per day,
whereas for controls it was 174·3 (0–567·6) mg per
day: a marginally significant difference in this small
sample size (U = 216, z = −1·9, p = ·053). Volume of
caffeinated beverage intake (mean ± SD ounces) did
not differ statistically between those with and without
a mental health diagnosis (77·1 ± 20·7 versus 70·4
± 24·3 ounces, respectively, p = ·36), but the trend
towards higher volume in the group with a mental
health diagnosis suggests this may be a limitation of
our sample size.
DISCUSSION
This study showed that women with a diagnosis of
depression, anxiety, post-traumatic stress disorder or
bipolar disorder and who have concomitant OAB may
have a disproportionate intake of caffeine (approxi-
mately 33% more in this study) when compared to
women with similar OAB symptoms but without a men-
tal health diagnosis. The women with a mental health
diagnosis studied here, preferentially selected more
highly caffeinated drinks as their beverage of choice,
perhaps to positively affect mood.
Results of this small pilot work should be interpreted
with caution, but this initial investigation provides
beginning support for our working hypothesis that
caffeine, mental health conditions and OAB may be
linked. To our knowledge, this is the first time that
this link has been addressed with data. This may
be because collecting data at the level of precision
needed is difficult and burdensome. This study,
despite being small and a secondary analysis, had
the advantage of quantifying caffeine intake with far
greater detail than usually obtained on standard voiding
diaries, thus allowing more exact calculation of caffeine
consumption. Even with this higher precision, caffeine
sources from food, for instance a chocolate bar, were
not included, so the estimate of actual caffeine intake
may still be low.
We reiterate that the parent study was not
fully powered to address this secondary research
question, and the data should be considered pilot
with limited generalizability until findings are confirmed
by additional research. In addition, study groups may
not have been pure; for instance, those placed in
the control group may have actually had a mental
health problem, but had not sought help from a health
care provider, and as such did not have a formal
diagnosis. We also did not extensively investigate the
relationship between medications taken by the women
with mental health diagnoses, which may have differed
from those without diagnoses, and could possibly have
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Figure 3 Boxplots showing 3-day average of caffeine intake in milligrams by cases (subjects who had a mental health diagnosis) and controls.
influenced beverage intake, for instance in response
to side-effects, such as dry mouth. However, there
were no significant differences observed between the
volumes of total beverage intake in the two study
groups, suggesting volume increase alone was not
the contributing factor for OAB in women with mental
health diagnoses. Our study also did not describe the
caffeine intake profile before the onset of symptoms of
either depression or OAB and the retrospective design
does not allow determination of cause and effect.
CONCLUSION
Although replication of the findings is warranted,
this initial pilot work provides the first data, to our
knowledge, that caffeine intake may by higher in
women with mental health conditions and might
inadvertently produce or exacerbate symptoms of
OAB.
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a. USDA documents 12 mg per ounce for ‘‘Coffee, brewed from grounds, prepared with tap water.’’
b. Many other sites quoted other amounts depending on brand, origin of coffee, degree of roasting.
2. Decaf Coffee: USDA: ‘‘Coffee, brewed from grounds, prepared with tap water, decaffeinated’’ = 0 mg per
ounce, 2 mg per 8 ounces, ·25 mg per ounce.
3. Coffee: 1/2 decaf,
1/2 caf: 6·125 mg per ounce, per averaging the USDA caf with decaf.
4. Instant Coffee:
a. USDA: ‘‘Coffee, instant, regular, prepared with water’’ 8 mg per ounce.
5. Coke: per coca-cola website:
a. Coca-Cola classic: 23 mg per 8 ounces, 2·875 mg per ounce.
b. Decaf Coke: 0 mg per 8 ounces.
c. Diet Coke: 31 mg per 8 ounces, 3·875 mg per ounce.
6. Root Beer:
a. Barqs (per coca-cola website) 15 mg per 8 ounces, diet barqs & barq’s crème sodas = 0 mg per 8
ounces.
7. Pepsi: (Per Pepsi website) 25 mg per 8 ounces, 3·125 mg per ounce.
a. Diet Pepsi: 35 mg per 12 ounces, 2·917 mg per ounce.
b. Diet and Reg Mt Dew: 54 mg per 12 ounces.
8. Green Tea (not found in USDA):
a. Mayo Clinic: 8 ounces = 30–50 mg (Source: Center for Science in the Public Interest, 2007; The
Coca-Cola Co., 2007; PepsiCo Inc., 2007; Starbucks Corp., 2007; USDA National Nutrient Database
for Standard Reference, 2007). I will round and say 40 mg per 8 ounces, or 5 mg per ounce.
9. Black Tea:
a. 42–72 mg per 8 ounces. Average: 57 per 8 ounces, 7·125 mg per ounce Source: Astill C, Birch MR,
Dacombe C, Humphrey PG, Martin PT. Factors affecting the caffeine and polyphenol contents of black
and green tea infusions. J Agric Food Chem. 2001;49(11):5340–5347. (PubMed)
10. Chocolate Milk:
a. USDA: ‘‘Chocolate syrup, prepared with whole milk’’ = 6 mg per 8 ounces, ·75 mg per ounce.
11. Hot chocolate:
a. USDA: ‘‘Cocoa mix, powder, prepared with water’’ = 1 mg per ounce.
12. Folgers (From website)
a. Instant: 74 mg per 6ounces: 12·33 mg per ounce.
b. Regular: 59 mg per 6 ounces: 9·83 mg per ounce
c. Half-caff: 30 mg per 6 ounces: 5 mg per ounce.
d. Decaf: 2·8 mg per 6 ounces: 0·467 mg per ounce.
13. Tea:
a. USDA: ‘‘Tea, brewed, prepared with tap water’’ = 6 mg per ounce.
b. USDA: ‘‘Tea, brewed, prepared with tap water, decaffeinated’’ = 0 mg per ounce.
i Visual analogue scale adapted from Bower, Moore, and Adams, 2001.
ii Coyne, 2002
iii De Wachter S, 2003
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